JOURNEY MEDICAL CORPORATION

Analyst Reco. Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
3.57 ^USD	+3.78%		+1.71%	-38.02%

01/05	Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer	CI
21/03	Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target	16/02	MT
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating	07/12	MT
B. Riley Raises Journey Medical's PT to $6 From $3 On 'Impressive' Results From DFD-29 Study in Moderate to Severe Papulopustular Rosacea, Keeps Buy Rating	12/23/12	MT
B. Riley Cuts Journey Medical's Price Target to $3 From $6, Keeps Buy Rating	23/23/23	MT
B. Riley Lowers Journey Medical's Price Target to $6 From $10 After Q3 Topline Miss on Generic Competition, Keeps Buy Rating	14/22/14	MT
B. Riley Lowers Journey Medical's Price Target to $10 from $14, Keeps Buy Rating	11/22/11	MT
Cantor Fitzgerald Reinstates Journey Medical at Overweight with $9 Price Target	25/22/25	MT
Roth Capital Starts Journey Medical at Buy With $15 Price Target	16/21/16	MT
B. Riley Starts Journey Medical at Buy with $14 PT, Says Well-Positioned for Revenue, Earnings Growth	07/21/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW